4//SEC Filing
Greenleaf Peter 4
Accession 0001628280-23-006526
CIK 0001600620other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:27 PM ET
Size
7.3 KB
Accession
0001628280-23-006526
Insider Transaction Report
Form 4
Greenleaf Peter
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2023-03-02+667,407→ 1,015,718 total - Sale
Common Stock
2023-03-02$8.94/sh−32,750$292,785→ 982,968 total
Footnotes (5)
- [F1]Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date.
- [F2]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F3]Includes shares of common stock acquired by the reporting person pursuant to the Issuer's 2021 Employee Share Purchase Plan as follows: 1,221 shares of common stock were acquired on May 31, 2022 and 1,883 shares of common stock were acquired on November 30, 2022.
- [F4]The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 667,407 newly awarded RSUs, 312,240 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 32,967 shares of common stock. On March 2, 2023, 104,080 of Prior RSUs vested and 208,160 of Prior RSUs remained unvested.
- [F5]Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001363683
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:27 PM ET
- Size
- 7.3 KB